Mineralys Therapeutics
MLYS
13.66
-0.50
-3.53%
Mineralys Therapeutics
US · MLYS
#2760 by market cap
Listed 2023
13.66
-0.50
-3.53%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Mineralys Therapeutics
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
- Founded
- 2019
- CEO
- Mr. Jon Congleton
- Employees
- 76
- Headquarters
- Radnor, Pennsylvania, United States of America
- Fiscal year end
- 12-31
- Website
- mineralystx.com
Company profile
- Exchange
- US
- Symbol
- MLYS
- Market-cap rank
- #2760
- Listing date
- 2023-02-10
- Market cap
- 1.21B
- Float cap
- 911.75M
- Shares out
- 88.56M
- Float shares
- 66.75M
Sectors & themes
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Mineralys Therapeutics discussion 0 comments